ENEnveric Biosciences, Inc. ENVB · NASDAQ
$1.40 -4.11% (-$0.06)
- Market cap
- $6.27M
- Enterprise value
- -$2.03M
- P/E
- -
- Forward P/E
- -
- PEG
- -
- P/S
- -
- P/FCF
- -
- EV/EBITDA
- -
- ROIC
- -108.0%
- Gross margin
- -
- Net margin
- -
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -
- Beta
- 1.18
- Free float
- 96.9%
About the company
Enveric Biosciences Inc. (ENVB) is a biopharmaceutical company focused on developing innovative therapeutic products for the treatment of symptoms associated with cancer and other chronic diseases. The company specializes in the research and development of cannabinoid-based therapies and other natural compounds that offer patients hope for relief from pain, inflammation, and other challenges associated with illness.
Sector
Healthcare
Industry
Biotechnology
CEO
Joseph Edward Tucker
Employees
6
Headquarters
Cambridge
Valuation
Is today's price reasonable?
- What to watch: The share price is above the Bulios Fair Price.
Growth and estimates
Is it growing, and what comes next?
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
Financial health
Can it carry its debt?
- What speaks for it: It has no debt and holds $8.30M in cash.
- What to watch: It passes only 2 of the 9 points of the Piotroski financial health test.
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number